{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-070166","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.254701+00:00","generated_at":"2026-06-18T03:57:04.837948+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IO Biotech reports 2022 net loss of $71.5M; cash runway through Q3 2024","bullets":["Net loss $71.5M for 2022 vs $67.9M for 2021; Q4 net loss $20.1M vs $21.3M.","R&D expenses $47.0M (+56% YoY) driven by Phase 3 trial execution; G&A $24.4M (+120%).","Cash and equivalents $142.6M at Dec 31, 2022, down from $211.5M; expects runway through Q3 2024.","Phase 3 advanced melanoma trial (IOB-013) targets 75% enrollment by mid-2023; interim ORR analysis could enable accelerated BLA.","Appointed Amy Sullivan CFO (Oct 2022) and Devin Smith GC (Jan 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-070166","json":"https://secwatch.observer/filing/0001193125-23-070166.json","markdown":"https://secwatch.observer/filing/0001193125-23-070166.md","text":"https://secwatch.observer/filing/0001193125-23-070166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/0001193125-23-070166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/d464597d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:57:04.837948+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"574fc12b93ee6acb2189f58020311ff3a7a8aa1d","claim":"IO Biotech, Inc. reported the year ended December 31, 2022 results: net income $71.5 million.","evidence_excerpt":"Net loss for the year ended December 31, 2022, was $71.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1865494/000119312523070166/0001193125-23-070166-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$71.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}